C
24.47
-0.17 (-0.69%)
| Previous Close | 24.64 |
| Open | 24.36 |
| Volume | 51,561 |
| Avg. Volume (3M) | 1,244,258 |
| Market Cap | 3,007,665,920 |
| Price / Earnings (TTM) | 14.31 |
| Price / Earnings (Forward) | 9.97 |
| Price / Sales | 5.24 |
| Price / Book | 3.10 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2026 |
| Profit Margin | 36.91% |
| Operating Margin (TTM) | 44.81% |
| Diluted EPS (TTM) | 1.57 |
| Quarterly Revenue Growth (YOY) | 43.60% |
| Quarterly Earnings Growth (YOY) | 143.80% |
| Total Debt/Equity (MRQ) | 0.39% |
| Current Ratio (MRQ) | 6.14 |
| Operating Cash Flow (TTM) | 267.93 M |
| Levered Free Cash Flow (TTM) | 223.08 M |
| Return on Assets (TTM) | 18.59% |
| Return on Equity (TTM) | 29.11% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Catalyst Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.22% |
| % Held by Institutions | 83.18% |
| 52 Weeks Range | ||
| Median | 35.00 (43.03%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 03 Mar 2026 | 35.00 (43.03%) | Buy | 23.92 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies |
| 05 Jan 2026 | Announcement | The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) |
| 15 Dec 2025 | Announcement | Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |